Stephen E. Spurgeon

92 papers receiving 2.5k citations

Stephen E. Spurgeon's Hit Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia 2014 · 479 citations
4790+4+8Years since publication100200300400

Peers

Stephen E. Spurgeon
Comparison fields: 5 of 79
  • Genetics 1.5k
  • Pathology and Forensic Medicine 1.2k
  • Hematology 498
  • Oncology 629
  • Immunology 500
Replace Thomas E. Boyd with:
Thomas E. Boyd United States
Soham D. Puvvada United States
Andrew R. Pettitt United Kingdom
Leslie A. Andritsos United States
Ellen Schlette United States
Lori A. Gressick United States
Enrico Tiacci Italy
Nicole Lamanna United States
Kathryn S. Kolibaba United States
Sarah E. M. Herman United States
Stephen E. Spurgeon relative to Thomas E. Boyd United States Thomas E. Boyd's profile →
Citations per field
00.5×1.6×
Thomas E. Boyd · 1×
Citations per year

Countries citing papers authored by Stephen E. Spurgeon

Since Specialization
Citations

This map shows the geographic impact of Stephen E. Spurgeon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Spurgeon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Spurgeon more than expected).

Fields of papers citing papers by Stephen E. Spurgeon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen E. Spurgeon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Spurgeon. The network helps show where Stephen E. Spurgeon may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen E. Spurgeon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen E. Spurgeon Line = papers co-authored together Stephen E. Spurgeon links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Hit paper breakdown →
2014479
2 2014205
3 2014170
4 2016117
5 2012104
6 2010103
7 201092
8 201260
9 201160
10 201456
11 201656
12 201456
13 201853
14 201651
15 201348
16 200947
17 201542
18 201241
19 201339
20 201837

About Stephen E. Spurgeon

Stephen E. Spurgeon is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Molecular Biology and Hematology, having authored 99 papers that have together received 2.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (71 papers), Lymphoma Diagnosis and Treatment (47 papers), Immunodeficiency and Autoimmune Disorders (14 papers), Viral-associated cancers and disorders (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), CAR-T cell therapy research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Lymphoblastic Leukemia research (9 papers). The work is most often cited by research in Genetics (1.5k citations), Pathology and Forensic Medicine (1.2k citations), Hematology (498 citations), Oncology (629 citations) and Immunology (500 citations). Stephen E. Spurgeon has collaborated with scholars based in United States, India and Poland. Frequent co-authors include Ian W. Flinn, Richard R. Furman, Jennifer R. Brown, Steven Coutré, Nina D. Wagner‐Johnston, Brad S. Kahl, Sissy Peterman, Don M. Benson, Albert S. Yu and John C. Byrd. Their work appears in journals such as Blood, Journal of Clinical Oncology, Oncotarget, HemaSphere and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact